BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR

Key Points

• BlackRock acquired 5.17 million Voyager Therapeutics shares during the second quarter, valued at approximately $18.1 million and representing an 8.56% stake.
• Other institutional investors also increased their positions, with hedge funds and institutions collectively owning 48.03% of VYGR.
• Voyager shares recently traded at $3.38, while analysts maintained a “Moderate Buy” consensus with a $16.50 target price; the company reported a quarterly loss of $0.40 per share and $3.17 million in revenue.

BlackRock Inc. acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 5,172,063 shares of the company's stock, valued at approximately $18,102,000. BlackRock Inc. owned about 8.56% of Voyager Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of VYGR. AQR Capital Management LLC boosted its position in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after acquiring an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Voyager Therapeutics during the first quarter worth approximately $218,000. Acadian Asset Management LLC lifted its stake in Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Voyager Therapeutics by 1.1% in the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company's stock valued at $430,000 after purchasing an additional 6,748 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Trading Down 4.5%

Shares of NASDAQ VYGR opened at $3.38 on Friday. The stock has a market cap of $208.28 million, a P/E ratio of -1.88 and a beta of 1.32. Voyager Therapeutics, Inc. has a twelve month low of $2.93 and a twelve month high of $5.55. The stock has a 50 day moving average of $3.32 and a two-hundred day moving average of $3.68.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. Voyager Therapeutics had a negative net margin of 312.63% and a negative return on equity of 57.92%. The business had revenue of $3.17 million for the quarter, compared to analysts' expectations of $4.52 million. As a group, research analysts predict that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VYGR. HC Wainwright reissued a "buy" rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. Wall Street Zen downgraded shares of Voyager Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source